Alexander V Lopachev

Dr. Alexander V Lopachev

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 May 2016 in Biochemistry (Moscow)
Verified
Journal Article
Closed access
PDF file
ALAlexander V Lopachev
Alexander V Lopachev
OLO. M. Lopacheva
O. M. Lopacheva
DAD. A. Abaimov
D. A. Abaimov
OKO. V. Koroleva
O. V. Koroleva
EVE. A. Vladychenskaya
E. A. Vladychenskaya
TFT. N. Fedorova
T. N. Fedorova
Dipeptide carnosine (β-alanyl-L-histidine) is a natural antioxidant, but its protective effect under oxidative stress induced by neurotoxins is studied insufficiently. In this work, we show the...

8 November 2014 in Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
EAEvgeny E. Akkuratov
Evgeny E. Akkuratov
OLOlga M. Lopacheva
Olga M. Lopacheva
MKMarkus Kruusmägi
Markus Kruusmägi
ALAlexander V Lopachev
Alexander V Lopachev
Zahoor A. ShahZahoor A. Shah
Zahoor A. Shah
LLLijun Liu
Lijun Liu

30 October 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
ALAlexander V Lopachev
Alexander V Lopachev
AVAnna B. Volnova
Anna B. Volnova
AEAnna Evdokimenko
Anna Evdokimenko
DADenis Abaimov
Denis Abaimov
YTYulia Timoshina
Yulia Timoshina
Raul R GainetdinovRaul R Gainetdinov
Raul R Gainetdinov
Intracerebroventricular (ICV) administration of ouabain, an inhibitor of the Na, K-ATPase, is an approach used to study the physiological functions of the Na, K-ATPase and cardiotonic steroids in the central nervous system, known to cause mania-like hyperactivity in rats. We describe a mouse model of ouabain-induced mania-like behavior. ICV administration of 0.5 µl of 50 µM (25 pmol, 14.6 ng) ouabain into each lateral brain ventricle results in increased locomotor activity, stereotypical behavior, and decreased anxiety level an hour at minimum. Fast-scan cyclic voltammetry showed that administration of 50 µM ouabain causes a drastic drop in dopamine uptake rate, confirmed by elevated concentrations of dopamine metabolites detected in the striatum 1 h after administration. Ouabain administration also caused activation of Akt, deactivation of GSK3β and activation of ERK1/2 in the striatum of ouabain-treated mice. All of the abovementioned effects are attenuated by haloperidol (70 µg/kg intraperitoneally). Observed effects were not associated with neurotoxicity, since no dystrophic neuron changes in brain structures were demonstrated by histological analysis. This newly developed mouse model of ouabain-induced mania-like behavior could provide a perspective tool for studying the interactions between the Na,K-ATPase and the dopaminergic system.

Verified
Journal Article
Open access
PDF file
DCDmitry Chistyakov
Dmitry Chistyakov
NANadezda Azbukina
Nadezda Azbukina
ALAlexander V Lopachev
Alexander V Lopachev
KKKsenia N. Kulichenkova
Ksenia N. Kulichenkova
AAAlina A. Astakhova
Alina A. Astakhova
MSMarina Sergeeva
Marina Sergeeva
An antidiabetic drug of the thiazolidinedione class, rosiglitazone (RG) demonstrates anti-inflammatory properties in various brain pathologies. The mechanism of RG action in brain cells is not fully known. To unravel mechanisms of RG modulation of toll-like receptor (TLR) signaling pathways, we compare primary rat neuron and astrocyte cultures stimulated with the TLR4 agonist lipopolysaccharide (LPS) and the TLR3 agonist poly I:C (PIC). Both TLR agonists induced tumor necrosis factor (TNFα) release in astrocytes, but not in neurons. Neurons and astrocytes released interleukin-10 (IL-10) and prostaglandin E2 (PGE2) in response to LPS and PIC. RG decreased TLR-stimulated TNFα release in astrocytes as well as potentiated IL-10 and PGE2 release in both astrocytes and neurons. RG induced phosphorylation of p38 and JNK MAPK (mitogen-activated protein kinase) in neurons. The results reveal new role of RG as a modulator of resolution of neuroinflammation.

1 June 2018 in Regulatory Toxicology and Pharmacology
Verified
Journal Article
Closed access
OKOlga Kulikova
Olga Kulikova
DBDaniil Berezhnoy
Daniil Berezhnoy
SSSergey L. Stvolinsky
Sergey L. Stvolinsky
ALAlexander V Lopachev
Alexander V Lopachev
VOValentina S. Orlova
Valentina S. Orlova
TFTatiana Fedorova
Tatiana Fedorova

30 September 2022 in Composites Part B: Engineering
Verified
Journal Article
Closed access
MBMarie Barshutina
Marie Barshutina
SKS.O. Kirichenko
S.O. Kirichenko
VWV.A. Wodolajsky
V.A. Wodolajsky
ALAlexander V Lopachev
Alexander V Lopachev
SBS.N. Barshutin
S.N. Barshutin
PMPavel Musienko
Pavel Musienko